Gain Therapeutics (GANX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

GANX Stock Forecast

Gain Therapeutics stock forecast is as follows: an average price target of $7.00 (represents a 314.20% upside from GANX’s last price of $1.69) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.

GANX Price Target

The average price target for Gain Therapeutics (GANX) is $7.00 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $4.00. This represents a potential 314.20% upside from GANX's last price of $1.69.

GANX Analyst Ratings

Buy

According to 14 Wall Street analysts, Gain Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for GANX stock is 0 'Strong Buy' (0.00%), 12 'Buy' (85.71%), 1 'Hold' (7.14%), 1 'Sell' (7.14%), and 0 'Strong Sell' (0.00%).

Gain Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 09, 2022	-	Chardan Capital	$4.00	$3.15	26.98%	136.69%
Nov 13, 2022	Thomas Shrader	BTIG	$10.00	$3.21	211.53%	491.72%

Row per page

Go to

The latest Gain Therapeutics stock forecast, released on Dec 09, 2022 by Chardan Capital company, set a price target of $4.00, which represents a 26.98% increase from the stock price at the time of the forecast ($3.15), and a 136.69% increase from GANX last price ($1.69).

Gain Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$1.69	$1.69	$1.69
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Gain Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Gain Therapeutics's last price of $1.69. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 01, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 03, 2024	Maxim Group	Buy	Buy	Hold
Sep 03, 2024	H.C. Wainwright	Buy	Buy	Hold
Jul 02, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 12, 2023	Macquarie	-	Outperform	Initialise
Sep 12, 2023	Cowen & Co.	-	Outperform	Initialise
Sep 12, 2023	Canaccord Genuity	-	Buy	Initialise
Sep 12, 2023	Seaport Global	-	Sell	Initialise
Sep 12, 2023	RBC Capital	-	Outperform	Initialise
Sep 12, 2023	Deutsche Bank	-	Buy	Initialise

Row per page

Go to

Gain Therapeutics's last stock rating was published by H.C. Wainwright on Oct 01, 2024. The company gave GANX a "Buy" rating, the same as its previous rate.

Gain Therapeutics Financial Forecast

Gain Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Mar 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	$55.18K	-	$95.10K	$45.01K	-	$15.97K	$5.27K
Avg Forecast	$50.00K	$50.00K	$50.00K	$50.00K	$23.33K	$10.00K	$400.00K	$120.00K	$250.00K	$337.50K	$1.01M	$10.00K	$51.50K	$31.67K	$39.00K	$51.60K	$20.00K	$4.96K
High Forecast	$50.00K	$50.00K	$50.00K	$50.00K	$23.33K	$10.00K	$400.00K	$120.00K	$250.00K	$337.50K	$1.01M	$10.00K	$51.50K	$31.67K	$39.00K	$51.60K	$20.00K	$5.96K
Low Forecast	$50.00K	$50.00K	$50.00K	$50.00K	$23.33K	$10.00K	$400.00K	$120.00K	$250.00K	$337.50K	$1.01M	$10.00K	$51.50K	$31.67K	$39.00K	$51.60K	$20.00K	$3.97K
# Analysts	1	1	1	1	3	1	2	2	4	1	1	1	1	1	2	3	4	7
Surprise %	-	-	-	-	-	-	-	-	-	-	-	5.52%	-	3.00%	1.15%	-	0.80%	1.06%

Gain Therapeutics's average Quarter revenue forecast for Jun 23 based on 1 analysts is $1.01M, with a low forecast of $1.01M, and a high forecast of $1.01M. GANX's average Quarter revenue forecast represents a 1725.16% increase compared to the company's last Quarter revenue of $55.18K (Mar 23).

Gain Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Mar 21
# Analysts	1	1	1	1	3	1	2	2	4	1	1	1	1	1	2	3	4	7
EBITDA	-	-	-	-	-	-	-	-	$-4.41M	$-4.89M	$-7.73M	$-5.19M	$-4.78M	$-5.22M	$-3.30M	-	$-4.65M	$-2.44M
Avg Forecast	$-50.00K	$-50.00K	$-50.00K	$-50.00K	$-23.33K	$-10.00K	$-400.00K	$-120.00K	$-250.00K	$-337.50K	$-1.01M	$-10.00K	$-51.50K	$-31.67K	$-4.06M	$-51.60K	$-20.00K	$-1.02M
High Forecast	$-50.00K	$-50.00K	$-50.00K	$-50.00K	$-23.33K	$-10.00K	$-400.00K	$-120.00K	$-250.00K	$-337.50K	$-1.01M	$-10.00K	$-51.50K	$-31.67K	$-3.25M	$-51.60K	$-20.00K	$-819.18K
Low Forecast	$-50.00K	$-50.00K	$-50.00K	$-50.00K	$-23.33K	$-10.00K	$-400.00K	$-120.00K	$-250.00K	$-337.50K	$-1.01M	$-10.00K	$-51.50K	$-31.67K	$-4.87M	$-51.60K	$-20.00K	$-1.23M
Surprise %	-	-	-	-	-	-	-	-	17.63%	14.47%	7.68%	518.69%	92.75%	164.73%	0.81%	-	232.71%	2.39%

undefined analysts predict GANX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Gain Therapeutics's previous annual EBITDA (undefined) of $NaN.

Gain Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Mar 21
# Analysts	1	1	1	1	3	1	2	2	4	1	1	1	1	1	2	3	4	7
Net Income	-	-	-	-	-	-	-	-	$-4.57M	$-4.72M	$-7.69M	$-5.14M	$-4.56M	$-5.09M	$-3.27M	-	$-4.66M	$-2.45M
Avg Forecast	$-4.91M	$-4.91M	$-5.04M	$-5.44M	$-5.59M	$-5.50M	$-5.17M	$-8.25M	$-8.28M	$-11.83M	$-8.17M	$-10.45M	$-8.60M	$-5.81M	$-4.07M	$-9.24M	$-6.82M	$-1.03M
High Forecast	$-4.91M	$-4.91M	$-5.04M	$-5.44M	$-5.34M	$-5.50M	$-5.17M	$-8.25M	$-7.76M	$-11.83M	$-8.17M	$-10.45M	$-8.60M	$-5.81M	$-3.25M	$-9.24M	$-6.82M	$-821.48K
Low Forecast	$-4.91M	$-4.91M	$-5.04M	$-5.44M	$-5.85M	$-5.50M	$-5.17M	$-8.25M	$-8.54M	$-11.83M	$-8.17M	$-10.45M	$-8.60M	$-5.81M	$-4.88M	$-9.24M	$-6.82M	$-1.23M
Surprise %	-	-	-	-	-	-	-	-	0.55%	0.40%	0.94%	0.49%	0.53%	0.87%	0.80%	-	0.68%	2.39%

Gain Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GANX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Gain Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Mar 21
# Analysts	1	1	1	1	3	1	2	2	4	1	1	1	1	1	2	3	4	7
SG&A	-	-	-	-	-	-	-	-	$2.03M	$2.52M	$3.74M	$2.49M	$2.79M	$2.69M	$1.78M	-	$2.19M	$1.05M
Avg Forecast	$3.62M	$3.62M	$3.62M	$3.62M	$1.69M	$723.32K	$28.93M	$8.68M	$18.08M	$24.41M	$72.85M	$723.32K	$3.72M	$2.29M	$2.81M	$3.72M	$1.44M	$358.31K
High Forecast	$3.62M	$3.62M	$3.62M	$3.62M	$1.69M	$723.32K	$28.93M	$8.68M	$18.08M	$24.41M	$72.85M	$723.32K	$3.72M	$2.29M	$2.81M	$3.72M	$1.44M	$429.90K
Low Forecast	$3.62M	$3.62M	$3.62M	$3.62M	$1.69M	$723.32K	$28.93M	$8.68M	$18.08M	$24.41M	$72.85M	$723.32K	$3.72M	$2.29M	$2.81M	$3.72M	$1.44M	$286.57K
Surprise %	-	-	-	-	-	-	-	-	0.11%	0.10%	0.05%	3.45%	0.75%	1.18%	0.63%	-	1.51%	2.93%

Gain Therapeutics's average Quarter SG&A projection for Mar 24 is $8.68M, based on 2 Wall Street analysts, with a range of $8.68M to $8.68M. The forecast indicates a 326.89% rise compared to GANX last annual SG&A of $2.03M (Dec 23).

Gain Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Mar 21
# Analysts	1	1	1	1	3	1	2	2	4	1	1	1	1	1	2	3	4	7
EPS	-	-	-	-	-	-	-	-	$-0.29	$-0.37	$-0.62	$-0.43	$-0.38	$-0.43	$-0.28	-	$-0.39	$-0.50
Avg Forecast	$-0.18	$-0.18	$-0.19	$-0.20	$-0.21	$-0.21	$-0.19	$-0.31	$-0.31	$-0.45	$-0.31	$-0.39	$-0.45	$-0.30	$-0.35	$-0.48	$-0.36	$-0.32
High Forecast	$-0.18	$-0.18	$-0.19	$-0.20	$-0.20	$-0.21	$-0.19	$-0.31	$-0.29	$-0.45	$-0.31	$-0.39	$-0.45	$-0.30	$-0.35	$-0.48	$-0.36	$-0.32
Low Forecast	$-0.18	$-0.18	$-0.19	$-0.20	$-0.22	$-0.21	$-0.19	$-0.31	$-0.32	$-0.45	$-0.31	$-0.39	$-0.45	$-0.30	$-0.35	$-0.48	$-0.36	$-0.32
Surprise %	-	-	-	-	-	-	-	-	0.93%	0.83%	2.01%	1.09%	0.85%	1.42%	0.81%	-	1.10%	1.58%

According to undefined Wall Street analysts, Gain Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GANX previous annual EPS of $NaN (undefined).

Gain Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INAB	IN8bio	$0.33	$14.00	4142.42%	Buy
LIFE	aTyr Pharma	$1.90	$11.00	478.95%	Buy
MOLN	Molecular Partners	$5.83	$29.00	397.43%	Buy
GANX	Gain Therapeutics	$1.69	$7.00	314.20%	Buy
CUE	Cue Biopharma	$1.10	$4.33	293.64%	Buy
ANEB	Anebulo Pharmaceuticals	$1.53	$6.00	292.16%	Buy
ELYM	Eliem Therapeutics	$5.11	$13.00	154.40%	Buy
CELC	Celcuity	$12.46	$31.50	152.81%	Buy
ELVN	Enliven Therapeutics	$24.90	$39.50	58.63%	Buy
NAMS	NewAmsterdam Pharma Company	$24.66	$36.50	48.01%	Buy
CYT	Cyteir Therapeutics	$3.02	$2.00	-33.77%	Sell

GANX Forecast FAQ

Is Gain Therapeutics a good buy?

Yes, according to 14 Wall Street analysts, Gain Therapeutics (GANX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 85.71% of GANX's total ratings.

What is GANX's price target?

Gain Therapeutics (GANX) average price target is $7 with a range of $4 to $10, implying a 314.20% from its last price of $1.69. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Gain Therapeutics stock go up soon?

According to Wall Street analysts' prediction for GANX stock, the company can go up by 314.20% (from the last price of $1.69 to the average price target of $7), up by 491.72% based on the highest stock price target, and up by 136.69% based on the lowest stock price target.

Can Gain Therapeutics stock reach $3?

GANX's average twelve months analyst stock price target of $7 supports the claim that Gain Therapeutics can reach $3 in the near future.

What are Gain Therapeutics's analysts' financial forecasts?

Gain Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $553.33K (high $553.33K, low $553.33K), average EBITDA is $-553K (high $-553K, low $-553K), average net income is $-24.506M (high $-24.252M, low $-24.76M), average SG&A $40.02M (high $40.02M, low $40.02M), and average EPS is $-0.924 (high $-0.914, low $-0.933). GANX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $200K (high $200K, low $200K), average EBITDA is $-200K (high $-200K, low $-200K), average net income is $-20.297M (high $-20.297M, low $-20.297M), average SG&A $14.47M (high $14.47M, low $14.47M), and average EPS is $-0.765 (high $-0.765, low $-0.765).

Did the GANX's actual financial results beat the analysts' financial forecasts?

Based on Gain Therapeutics's last annual report (Dec 2023), the company's revenue was $55.18K, which missed the average analysts forecast of $1.6M by -96.56%. Apple's EBITDA was $-22.253M, beating the average prediction of $-1.605M by 1286.81%. The company's net income was $-22.268M, missing the average estimation of $-38.733M by -42.51%. Apple's SG&A was $10.79M, missing the average forecast of $116.07M by -90.71%. Lastly, the company's EPS was $-1.71, beating the average prediction of $-1.46 by 17.13%. In terms of the last quarterly report (Mar 2023), Gain Therapeutics's revenue was $55.18K, beating the average analysts' forecast of $10K by 451.80%. The company's EBITDA was $-5.187M, beating the average prediction of $-10K by 51769.42%. Gain Therapeutics's net income was $-5.137M, missing the average estimation of $-10.453M by -50.85%. The company's SG&A was $2.49M, beating the average forecast of $723.32K by 244.77%. Lastly, the company's EPS was $-0.43, beating the average prediction of $-0.394 by 9.15%